Monitor May 7, 2026 earnings call for updated guidance on Brazil exposure and therapeutic registration progress. Assess whether new registrations materialize before the ban takes effect, as failure could materially impact future revenue.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 28 $54.29entry
- T+1 · 7mo ago −1.11%α −1.10% · $53.69
- T+5 · 7mo ago +0.72%α −0.97% · $54.68
- T+20 · 6mo ago −37.96%α −43.43% · $33.68
- T+60 · 4mo ago −37.30%α −41.29% · $34.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phibro Animal Health disclosed a Brazilian regulatory ban on antimicrobial growth promoters including its virginiamycin and bacitracin products, effective after a 180-day transition period. The company expects limited FY2026 impact and is pursuing therapeutic registrations to mitigate long-term effects.
Key Facts
- Brazilian MAPA Ordinance No. 1617 prohibits use of virginiamycin and bacitracin as growth promoters effective 180 days from April 27, 2026.
- During transition period, sales and use under current labels continue.
- Phibro expects limited impact on fiscal year 2026 results.
- New registrations for therapeutic use of virginiamycin in cattle and broiler chickens are in final MAPA review and expected during transition.
- Bacitracin already carries therapeutic claims in Brazil.
- PhibroVet digital platform will facilitate veterinary prescriptions post-ban.
Financial Impact
Limited impact on FY2026 results; no specific dollar amounts provided.
Risk Factors
- Therapeutic registrations may not be approved before the ban takes effect, leading to revenue loss in Brazil.
- Other markets could adopt similar restrictions on antimicrobial growth promoters.
- Uncertainty about the magnitude of long-term financial impact beyond FY2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-049485 |
| Document: tm2612861d1_ex99-1.htm | 0001104659-26-049485 |
| Document: 0001104659-26-049485-index-headers.html | 0001104659-26-049485 |
| Document: 0001104659-26-049485-index.html | 0001104659-26-049485 |
| Document: 0001104659-26-049485.txt | 0001104659-26-049485 |
Track record
9 reports on PAHC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $35.40 to $35.46 Now $35.02 −1.07% ▲ +0.17% −3.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $39.43 to $35.15 Now $35.02 −11.18% ▼ −10.85% −9.94% vs SPY
- Oct 19, 202628d ago SC 13G/A Bearish 5/10 Entry $38.80 to $38.38 Now $35.02 +9.74% ▲ +1.08% +1.16% vs SPY
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $36.95 to $36.01 Now $35.02 −5.22% ▼ −2.54% −8.07% vs SPY
- Jun 26, 202620w ago 8-K Neutral 2/10 Entry $31.81 to $34.13 Now $35.02 +10.09% ▲ +7.29% +5.91% vs SPY
- May 6, 202627w ago 8-K Bullish 6/10 Entry $43.16 to $35.26 Now $35.02 −18.86% ▼ −18.30% −19.81% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $58.50 to $36.58 Now $35.02 −40.14% ▼ −37.47% −38.60% vs SPY
- Apr 30, 202628w ago 8-K Neutral 4/10 Entry $54.66 to $39.83 Now $35.02 −35.93% ▼ −27.13% −29.47% vs SPY
- Apr 27, 202629w ago 8-K Bearish 5/10 Viewing Entry $54.29 to $54.68 Now $35.02 +35.49% ▼ −0.72% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers